Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ENZ, DX, ETY, ID - Market Report From DrStockPick.com!

drstock-2-3

signup3m

http://pennyomega.com/img/enz.jpg

Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”

“Moreover, in the first quarter, we achieved several milestones. We submitted Colon Sentry, a unique assay for risk-stratification of colon cancer occurrence, to the New York State Department of Health for approval. In addition, we began enrolling the first patients in our clinical trial of Optiquel™, our candidate therapeutic for the treatment of autoimmune uveitis. We also continued to roll out proprietary products and systems designed to aid in drug development,” he added.

Enzo Clinical Labs ("Lab") benefited in the quarter from increased market share and service volume increases in connection with its being named a participating provider for Empire BlueCross BlueShield in the metropolitan New York area.

Enzo Life Sciences’ profitability for the quarter improved due to benefits from the plan instituted in July to integrate functions and rationalize workforce levels.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Eastern Pennsylvania and New Jersey.

***************************************

Dynex Capital Inc (NYSE:DX) announced on Dec 17, 2010 that it closed a public offering of 6,900,000 shares of its common stock, including 900,000 shares pursuant to an option that was fully exercised by the underwriters, at a public offering price of $10.20 per share for total net proceeds of approximately $67.5 million, after deduction of underwriting discounts and commissions and estimated expenses.

Dynex Capital, Inc., together with its subsidiaries, operates as a mortgage real estate investment trust (REIT). The company primarily invests in mortgage-backed securities issued or guaranteed by a federally chartered corporation, commercial mortgage-backed securities, and non-agency residential mortgage-backed securities, as well as securitized residential and commercial mortgage loans.

***************************************

Eaton Vance Tax-Managed Diversified Equity Income Fund (NYSE:ETY) announced on Dec 14, 2010 the quarterly distributions declared on the common shares of two of its closed-end equity funds (the “Funds”). The record date for the distributions is February 18, 2011, and the payable date is February 28, 2011. The ex-date is February 16, 2011.

Eaton Vance Tax-Managed Diversified Equity Income Fund is a closed ended equity mutual fund launched and managed by Eaton Vance Management. The fund invests in the public equity markets across the globe. It invests in the stocks of companies operating across diversified sectors. Eaton Vance Tax-Managed Diversified Equity Income Fund was formed on November 30, 2006 and is domiciled in the United States.

***************************************

L-1 Identity Solutions Inc. (NYSE:ID) a leading supplier of identity solutions and services, announced that a special meeting of stockholders to vote on the previously announced merger transaction with Safran SA has been scheduled to be held at the Hyatt Regency-Greenwich hotel located at 1800 E Putnam Ave, Old Greenwich, CT. on February 3, 2011 at 2 p.m. Eastern Time. L-1 stockholders of record as of the close of business on December 27, 2010 will be entitled to receive notice of, and voting materials relating to, the special meeting.

L-1 Identity Solutions, Inc. provides technology, products, systems and solutions, and services to protect and secure personal identities and assets in the United States and internationally. The company operates in two segments, Solutions and Services. The Solutions segment offers secure credentialing solutions, including building and maintenance of secure process for ID production.

**********************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

drstbc